Faraz Ali, Tenaya
October 3, 2019 08:17 AM EDTUpdated 10:43 AM
Startups
Cell/Gene Tx

San Fran­cis­co biotech has its heart in heart fail­ure — and $92M in the bank

Natalie Grover

Reporter

When a sala­man­der’s heart suf­fers dam­age, the am­phib­ian’s cells are able to di­vide and re­pair the or­gan. Tenaya Ther­a­peu­tics wants to em­pow­er your heart with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Louisiana's Bill Cas­sidy named next chair of Sen­ate health com­mit­tee

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times